Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

Key Terms

high-content screening technical

High-content screening is an automated laboratory method that takes and analyzes large numbers of clear, detailed microscope images of cells to see how they respond to chemicals or genetic changes. Think of it as photographing thousands of tiny experiments and using software to spot useful patterns and side effects that a single number wouldn’t show. For investors, it matters because it can speed up drug discovery, reveal safety issues earlier, and make development programs more data-driven and potentially less risky.

multimode plate reader technical

A multimode plate reader is a laboratory instrument that measures chemical or biological signals from many tiny test wells on a flat tray using several detection methods (for example color change, glow, or fluorescence), like a camera with different filters scanning many samples at once. For investors, demand for these instruments indicates activity in drug discovery, diagnostics and research labs, so sales and upgrades can signal revenue growth, recurring consumable sales and broader R&D or testing spending trends.

organoids medical

Miniaturized, simplified versions of human organs grown in the lab from stem cells that mimic key structure and function of real tissues. Like scale models used by architects, organoids let researchers test drugs, study disease and predict how human tissues will respond without using whole patients, which can speed development, reduce costs and lower risk for investors evaluating biotech pipelines and therapies.

organ-on-chip medical

A small laboratory device that recreates key functions of a human organ on a micro scale by using living cells and tiny channels to mimic blood flow and tissue structure. Like a flight simulator for drugs, it lets developers test safety and effectiveness faster and cheaper than full clinical trials, reducing development risk, time and cost and potentially improving the odds and timing of a product reaching the market—information investors use to value biotech and medical-technology companies.

21 CFR Part 11 regulatory

21 CFR Part 11 is a U.S. regulatory rule that sets requirements for how electronic records and electronic signatures must be created, stored and protected so they can be trusted as if they were paper documents. For investors, it matters because companies that handle regulated data—like clinical trial results or manufacturing logs—must meet these controls or face regulatory delays, fines or lost market access; think of it as a lock-and-audit trail for digital paperwork.

New launches in high-content imaging, detection, and automation help labs accelerate drug discovery workflows from sample to insight

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation.

At booth #612, Revvity will showcase an expanded portfolio of integrated workflow solutions designed to support discovery programs from early screening through data-driven decision making. Solutions debuting at SLAS2026 include:

• Opera Phenix OptIQ high-content screening system: Designed to reduce bottlenecks in phenotypic screening and advanced cellular analysis, this system enables quantitative imaging across complex biological models, including 3D organoids and organ-on-chip systems. Peak camera quantum efficiency has increased from 60% to 95%, improving image sensitivity and data quality, and the system is equipped with Phenologic.AI image analysis software that now includes new classification capabilities, such as cell cycle analysis, expanding beyond its previous focus on segmentation. Laser-based autofocus has been enhanced to better support multi-layer sample carriers, and a new Harmony™ software building block enables detection of organoids in brightfield image stacks.
• EnVision Nexus One multimode plate reader: The newest addition to the EnVision Nexus family, the EnVision Nexus One delivers the trusted sensitivity and reliability of the Envision Nexus platform in a streamlined single-detector configuration optimized for high-throughput screening environments. Designed to simplify automation and integration while supporting evolving assay needs, the system provides enhanced sensitivity across TRF, Alpha, and luminescence detection. The EnVision Nexus One is powered by intuitive Kaleido™ software with 21 CFR Part 11 compliance tools and offers flexible configuration options to support a wide range of laboratory workflows.
• AssayMate workstation: The compact, benchtop AssayMate liquid handler delivers intelligent automation performance for labs of any size. It supports a wide volume range of 3–1000 µL without requiring head changes, using a fixed 8-channel head and gripper configuration. Intelligent features such as pressure-based liquid level detection (PLLD) and built-in workflow error handling—including detection of missing plate lids—enable reliable operation and quick experiment resumption. A reconfigurable recessed deck accommodates optional modules such as heater shakers, heater coolers, and magnetic blocks, while AssayPREP™ software provides a user-friendly, drag-and-drop interface that requires minimal training.

“SLAS2026 marks a key milestone for Revvity with the introduction of new platforms that support the evolving needs of discovery labs,” said Kevin Quick, vice president, platforms, Revvity. “These launches integrate automation, trusted assay technologies, and AI-driven imaging to help customers accelerate results while maintaining data quality.”

For more information on Revvity’s new product launches, demonstrations, and conference activities at SLAS2026, visit booth #612 or this link.

For research use only. Not for use in diagnostic procedures.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205915069/en/

Investor Relations

Steve Willoughby

steve.willoughby@revvity.com

Media Relations

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity